Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth/Progenics’ Relistor Fails Second Phase III POI Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Companies also report positive Phase II results for an oral formulation in opioid-induced constipation.

You may also be interested in...



Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals

"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth

Tranzyme’s TZP-101 Proof-of-Concept Study Bodes Well For Deal, CEO Says

Compound’s promising Phase IIb results should pave the way to an exit for the North Carolina biotech.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel